Book contents
- Neurocritical Care
- Neurocritical Care
- Copyright page
- Contents
- Contributors
- Preface
- Chapter 1 The Neurological Assessment of the Critically Ill Patient
- Chapter 2 Cerebral Blood Flow Physiology and Metabolism in the Neurocritical Care Unit
- Chapter 3 Cerebral Edema and Intracranial Pressure in the Neurocritical Care Unit
- Chapter 4 Hypothermia in the Neurocritical Care Unit: Physiology and Applications
- Chapter 5 Analgesia, Sedation, and Paralysis in the Neurocritical Care Unit
- Chapter 6 Airway Management and Mechanical Ventilation in the Neurocritical Care Unit
- Chapter 7 Neuropharmacology in the Neurocritical Care Unit
- Chapter 8 Intracranial Monitoring in the Neurocritical Care Unit
- Chapter 9 Electrophysiologic Monitoring in the Neurocritical Care Unit
- Chapter 10 The Role of Transcranial Doppler as a Monitoring Tool in the Neurocritical Care Unit
- Chapter 11 Ischemic Stroke in the Neurocritical Care Unit
- Chapter 12 Intracerebral Hemorrhage in the Neurocritical Care Unit
- Chapter 13 Management of Cerebral Venous Thrombosis in the Neurocritical Care Unit
- Chapter 14 Subarachnoid Hemorrhage in the Neurocritical Care Unit
- Chapter 15 Status Epilepticus in the Neurocritical Care Unit
- Chapter 16 Neuromuscular Disorders in the Neurocritical Care Unit
- Chapter 17 Management of Head Trauma in the Neurocritical Care Unit
- Chapter 18 Management of Autoimmune Encephalitis in the Neurocritical Care Unit
- Chapter 19 Management of Cerebral Salt-Wasting Syndrome and Syndrome of Inappropriate Antidiuresis in the Neurocritical Care Unit
- Chapter 20 Brain Death in the Neurocritical Care Unit
- Chapter 21 Neuroterrorism and Drug Overdose in the Neurocritical Care Unit
- Chapter 22 Infections of the Central Nervous System in the Neurocritical Care Unit
- Chapter 23 Management of the Spinal Cord Injury in the Neurocritical Care Unit
- Chapter 24 Postoperative Management in the Neurocritical Care Unit
- Chapter 25 Ethical Considerations in the Neurocritical Care Unit
- Chapter 26 Pulmonary Consult: Management of Severe Hypoxia in the Neurocritical Care Unit
- Chapter 27 Management of Refractory Arrhythmias in the Neurocritical Care Unit
- Chapter 28 An Infectious Diseases Consult in the Neurocritical Care Unit
- Chapter 29 A Nephrology Consult in the Neurocritical Care Unit
- Chapter 30 Management of Hepatic Encephalopathy in the Neurocritical Care Unit
- Chapter 31 Hypoxic Encephalopathy in the Neurocritical Care Unit
- Chapter 32 Management of Delirium in the Neurocritical Care Unit
- Chapter 33 Generalized Weakness in the Neurocritical Care Unit
- Chapter 34 Management of Severely Brain-Injured Patients Recovering from Coma in the Neurocritical Care Unit
- Chapter 35 Acute Demyelinating Disorders in the Neurocritical Care Unit
- Chapter 36 Building a Case for a Neurocritical Care Unit
- Chapter 37 Neurointensive (NCCU) Care Business Planning
- Index
- References
Chapter 7 - Neuropharmacology in the Neurocritical Care Unit
Published online by Cambridge University Press: 24 July 2019
Edited by
Book contents
- Neurocritical Care
- Neurocritical Care
- Copyright page
- Contents
- Contributors
- Preface
- Chapter 1 The Neurological Assessment of the Critically Ill Patient
- Chapter 2 Cerebral Blood Flow Physiology and Metabolism in the Neurocritical Care Unit
- Chapter 3 Cerebral Edema and Intracranial Pressure in the Neurocritical Care Unit
- Chapter 4 Hypothermia in the Neurocritical Care Unit: Physiology and Applications
- Chapter 5 Analgesia, Sedation, and Paralysis in the Neurocritical Care Unit
- Chapter 6 Airway Management and Mechanical Ventilation in the Neurocritical Care Unit
- Chapter 7 Neuropharmacology in the Neurocritical Care Unit
- Chapter 8 Intracranial Monitoring in the Neurocritical Care Unit
- Chapter 9 Electrophysiologic Monitoring in the Neurocritical Care Unit
- Chapter 10 The Role of Transcranial Doppler as a Monitoring Tool in the Neurocritical Care Unit
- Chapter 11 Ischemic Stroke in the Neurocritical Care Unit
- Chapter 12 Intracerebral Hemorrhage in the Neurocritical Care Unit
- Chapter 13 Management of Cerebral Venous Thrombosis in the Neurocritical Care Unit
- Chapter 14 Subarachnoid Hemorrhage in the Neurocritical Care Unit
- Chapter 15 Status Epilepticus in the Neurocritical Care Unit
- Chapter 16 Neuromuscular Disorders in the Neurocritical Care Unit
- Chapter 17 Management of Head Trauma in the Neurocritical Care Unit
- Chapter 18 Management of Autoimmune Encephalitis in the Neurocritical Care Unit
- Chapter 19 Management of Cerebral Salt-Wasting Syndrome and Syndrome of Inappropriate Antidiuresis in the Neurocritical Care Unit
- Chapter 20 Brain Death in the Neurocritical Care Unit
- Chapter 21 Neuroterrorism and Drug Overdose in the Neurocritical Care Unit
- Chapter 22 Infections of the Central Nervous System in the Neurocritical Care Unit
- Chapter 23 Management of the Spinal Cord Injury in the Neurocritical Care Unit
- Chapter 24 Postoperative Management in the Neurocritical Care Unit
- Chapter 25 Ethical Considerations in the Neurocritical Care Unit
- Chapter 26 Pulmonary Consult: Management of Severe Hypoxia in the Neurocritical Care Unit
- Chapter 27 Management of Refractory Arrhythmias in the Neurocritical Care Unit
- Chapter 28 An Infectious Diseases Consult in the Neurocritical Care Unit
- Chapter 29 A Nephrology Consult in the Neurocritical Care Unit
- Chapter 30 Management of Hepatic Encephalopathy in the Neurocritical Care Unit
- Chapter 31 Hypoxic Encephalopathy in the Neurocritical Care Unit
- Chapter 32 Management of Delirium in the Neurocritical Care Unit
- Chapter 33 Generalized Weakness in the Neurocritical Care Unit
- Chapter 34 Management of Severely Brain-Injured Patients Recovering from Coma in the Neurocritical Care Unit
- Chapter 35 Acute Demyelinating Disorders in the Neurocritical Care Unit
- Chapter 36 Building a Case for a Neurocritical Care Unit
- Chapter 37 Neurointensive (NCCU) Care Business Planning
- Index
- References
Summary
From protein binding alterations to frequent drug–drug interactions, from hypermetabolic states to anuria, there exists a multitude of reasons that the therapeutic interventions of choice must be individualized in a critically ill patient. The principles of clinical pharmacology provide the basis of optimizing a safe and effective drug regimen. The four major subdivisions of pharmacology include pharmacokinetics, pharmacodynamics, pharmacotherapeutics, and toxicology. Simply stated, pharmacokinetics and pharmacodynamics focus on what the body does to the drug and what the drug does to the body, respectively. The following pharmacokinetic and pharmacodynamics factors must be taken into consideration to optimize effectiveness and to minimize toxicity.
- Type
- Chapter
- Information
- Neurocritical Care , pp. 62 - 77Publisher: Cambridge University PressPrint publication year: 2019
References
Kress, JP, Pohlman, AS, O’Connor, MF, Hall, JB (2000). Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 342: 1471–1477.Google Scholar
Seder, DB, Riker, RR, Jagoda, A, Smith, WS, Weingart, SD (2012). Emergency neurological life support: airway, ventilation, and sedation. Neurocrit Care 17: S4-S20.Google Scholar
Mirski, MA, Muffelman, B, Ulatowski, JA, Hanley, DF (1995). Sedation for the critically ill neurologic patient. Crit Care Med 23: 2038–2053.Google Scholar
Teitelbaum, JS, Ayoub, O, Skrobik, Y (2011). A critical appraisal of sedation, analgesia and delirium in neurocritical care. Can J Neurol Sci 38: 815–825.CrossRefGoogle ScholarPubMed
Brophy, GM, Bell, R, Claassen, J, et al. (2012). Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 17: 3–23.CrossRefGoogle ScholarPubMed
Treiman, DM, Meyers, PD, Walton, NY, et al. (1988). A comparison of four treatments for generalized convulsive status epilepticus. Verterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 339: 792–798.Google Scholar
Rowe, AS, Goodwin, H, Brophy, GM, et al. (2014). Seizure prophylaxis in neurocritical care: A review of evidence-based support. Pharmacotherapy 34: 396–409.Google Scholar
Temkin, NR, Dikmen, SS, Wilensky, AJ, et al. (1990). A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med 8: 497–502.Google Scholar
Bratton, SL, Chestnut, RM, Ghajar, J et al. (2007). Guidelines for the management of severe traumatic brain injury. XIII. Antiseizure prophylaxis. J Neurotrauma 24: S83–86.Google Scholar
Chang, BS, Lowenstein, DH (2003). Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1: 10–16.CrossRefGoogle Scholar
Dikmen, SS, Temkin, NR, Miller, B, Machamer, J, Winn, HR (1991). Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures. JAMA 10: 1271–1277.Google Scholar
Temkin, NR, Dikmen, SS, Anderson, GD, et al. (1999). Valproate therapy for prevention of posttraumatic seizures: a randomized trial. J Neurosurg 4: 593–600.CrossRefGoogle Scholar
Szaflarski, JP, Sangha, KS, Lindsell, CJ, Shutter, LA (2010). Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care 2: 165–172.Google Scholar
Connolly, ES, Rabinstein, AA, Carhuapoma, JR, et al. (2012). Guidelines for the management of aneurysmal subarachnoid hemorrhage. Stroke 43: 1711–1737.Google Scholar
Diringer, MN, Bleck, TP, Claude Hemphill, J III, et al. (2011). Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus Conference. Neurocrit Care 2: 211–240.Google Scholar
Naidech, AM, Kreitner, KT, Janjua, N, et al. (2005). Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke 3: 583–587.Google Scholar
Rosengart, AJ, Juo, JD, Tolentino, J, et al. (2007). Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs. J Neurosurg 2: 253–260.CrossRefGoogle Scholar
The Brain Trauma Foundation, The American Association of Neurological Surgeons, The Joint Section on Neurotrauma and Critical Care (2000). Guidelines for cerebral perfusion pressure. J Neurotrauma 17: 507–511.Google Scholar
Kamel, H, Navi, BB, Nakagawa, K, Hemphill, JC 3rd, Ko, NU (2011). Hypertonic saline versus mannitol for the treatment of elevated intracranial pressure: a meta-analysis of randomized clinical trials. Crit Care Med 39(3): 554–559.CrossRefGoogle ScholarPubMed
Weant, KA, Martin, JE, Humphries, RL, Cook, AM (2010). Pharmacologic options for reducing the shivering response to therapeutic hypothermia. Pharmacotherapy 30: 830–841.Google Scholar
Doufas, AG, Lin, CM, Suleman, MI, et al. (2003). Dexmedetomidine and meperidine additively reduce the shivering threshold in humans. Stroke 34: 1218–1223.Google Scholar
Mokhtarani, M, Mahgoub, AN, Morioka, N, et al. (2001). Buspirone and meperidine synergistically reduce the shivering threshold. Anesth Analg 93: 1233–1239.Google Scholar
Arpino, PA, Greer, DM (2008). Practical pharmacologic aspects of therapeutic hypothermia after cardiac arrest. Pharmacotherapy 28: 102–111.Google Scholar
Choi, AH, Ko, SB, Presciutti, M, et al. (2011). Prevention of shivering during therapeutic temperature modulation: the Columbia anti-shivering protocol. Neurocrit Care 14: 389–394.CrossRefGoogle ScholarPubMed
Badjatia, N, Strongilis, E, Prescutti, M, et al. (2008). Metabolic impact of shivering during therapeutic temperature modulation: the Bedside Shivering Assessment Scale. Stroke 39: 3242–3247.Google Scholar
Diringer, MN, Bleck, TP, Claude Hemphill, J 3rd, et al. (2011). Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus Conference. Neurocrit Care 15: 211–240.Google Scholar
Connolly, ES Jr, Rabinstein, AA, Carhuapoma, JR, et al. (2012). Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 43: 1711–1737.Google Scholar
Ekelund, A, Reinstrup, P, Ryding, E, et al. (2002). Effects of iso- and hypervolemic hemodilution on regional cerebral blood flow and oxygen delivery for patients with vasospasm after aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien) 144: 703–712; discussion 712–713.Google Scholar
Lennihan, L, Mayer, SA, Fink, ME, et al. (2000). Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. Stroke 31: 383–391.Google Scholar
Egge, A, Waterloo, K, Sjoholm, H, et al. (2001). Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: a clinical, prospective, randomized, controlled study. Neurosurgery 49: 593–605; discussion 605–606.Google Scholar
Allen, GS, Ahn, HS, Preziosi, TJ, et al. (1983). Cerebral arterial spasm: a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 308: 619–624.CrossRefGoogle ScholarPubMed
Dorhout Mees, SM, Rinkel, GJ, Feigin, VL, et al. (2007). Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev CD000277.Google Scholar
Nimodipine [package insert]. Detroit, MI: Caraco Pharmaceutical Laboratories, Ltd; 2012. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6a161d9-7e7a-4711-ba0e-c9040c42268d (accessed December 2018).Google Scholar
Haley, EC Jr, Kassell, NF, Torner, JC (1993). A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 78: 537–547.Google Scholar
Haley, EC Jr, Kassell, NF, Torner, JC, Truskowski, LL, Germanson, TP (1994). A randomized trial of two doses of nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 80: 788–796.CrossRefGoogle ScholarPubMed
Dorhout Mees, SM, Algra, A, Vandertop, WP, et al. (2012). Magnesium for aneurysmal subarachnoid hemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet 380: 44–49.Google Scholar
Kramer, AH, Fletcher, JJ (2011). Locally-administered intrathecal thrombolytics following aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. Neurocrit Care 14: 489–499.Google Scholar
Badjatia, N, Topcuoglu, MA, Pryor, JC, et al. (2004). Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. Am J Neuroradiol 25: 819–826.Google Scholar
Ehtisham, A, Taylor, S, Bayless, L, et al. (2009). Use of intrathecal nicardipine for aneurysmal subarachnoid hemorrhage-induced cerebral vasospasm. South Med J 102: 150–153.Google Scholar
Goodson, K, Lapointe, M, Monroe, T, Chalela, JA (2008). Intraventricular nicardipine for refractory cerebral vasospasm after subarachnoid hemorrhage. Neurocrit Care 8: 247–252.Google Scholar
Webb, A, Kolenda, J, Martin, K, Wright, W, Samuels, O (2010). The effect of intraventricular administration on mean cerebral blood flow velocity measured by transcranial doppler in the treatment of vasospasm following aneurysmal subarachnoid hemorrhage. Neurocrit Care 12: 159–164.CrossRefGoogle ScholarPubMed
Schmidt, U, Bittner, E, Pivi, S, Marota, JJ (2010). Hemodynamic management and outcome of patients treated for cerebral vasospasm with intrarterial nicardipine and/or milrinone. Anesth Analg 110: 895–902.CrossRefGoogle ScholarPubMed
Albanese, E, Russo, A, Quiroga, M, et al. (2010). Ultrahigh-dose intraarterial infusion of verapamil through an indwelling microcatheter for medically refractory severe vasospasm: initial experience. J Neurosurg 113: 913–922.Google Scholar
Keuskamp, J, Murali, R, Chao, KH (2008). High-dose verapamil in the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg 108: 458–463.Google Scholar